{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:00:52Z","timestamp":1769065252919,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We previously showed the 2-year OS rate, the primary endpoint, of 90% in a phase II trial of gefitinib induction followed by chemoradiotherapy (CRT) in unresectable, stage III, EGFR-mutant, non-small-cell lung cancer (NSCLC). However, neither long-term survival data nor late-phase adverse event profiles have been presented.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and methods<\/jats:title>\n            <jats:p>Patients with unresectable, EGFR-mutant, stage III NSCLC were administered gefitinib monotherapy for 8\u00a0weeks. After confirming no disease progression during induction therapy, cisplatin and docetaxel on days 1, 8, 29, and 36 with concurrent radiotherapy at a total dose of 60\u00a0Gy were subsequently administered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the enrolled twenty patients, the 5-year OS rate and median survival time were 70.0% [95% confidence interval: 45.1\u201385.3] and 5.5\u00a0years [4.91-NE], respectively, whereas 5-year PFS rate and median PFS time were 15.0% (3.7\u201333.5) and 1.4\u00a0years [0.69\u20132.29], respectively. Efficacy did not seem influenced even if radiation field was re-planed in response to the effect of gefitinib induction. As for late adverse events, pulmonary fibrosis occurred in 7 patients (35%). The median time from completion of CRT to the occurrence of the event was 245\u00a0days. All were grade 1, and there was no evidence of cavitation of the lesions or chronic infections such as Aspergillus infection during the course of the disease. One case of small cell lung cancer occurred during the period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>With longer follow-up time, we demonstrated favorable efficacy with tolerable toxicity profiles in the EGFR-TKI induction followed by standard CRT in EGFR-mutant, stage III, NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration numbers<\/jats:title>\n            <jats:p>UMIN00005086. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000006047&amp;type=summary&amp;language=EjRCTs071180036\" ext-link-type=\"uri\">https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000006047&amp;type=summary&amp;language=EjRCTs071180036<\/jats:ext-link>. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs071180036\" ext-link-type=\"uri\">https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs071180036<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10147-025-02696-3","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:41:08Z","timestamp":1738773668000},"page":"497-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study"],"prefix":"10.1007","volume":"30","clinical-trial-number":[{"clinical-trial-number":"umin00005086","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0112-0843","authenticated-orcid":false,"given":"Katsuyuki","family":"Hotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daijiro","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Bessho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Gemba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Shioyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Katsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Sugio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2696_CR1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388","journal-title":"N Engl J Med"},{"key":"2696_CR2","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00280-018-3694-5","volume":"82","author":"N Oda","year":"2018","unstructured":"Oda N, Hotta K, Ninomiya K et al (2018) A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. Cancer Chemother Pharmacol 82:1031\u20131038","journal-title":"Cancer Chemother Pharmacol"},{"key":"2696_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00280-014-2425-9","volume":"73","author":"Y Kato","year":"2014","unstructured":"Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943\u2013950","journal-title":"Cancer Chemother Pharmacol"},{"key":"2696_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-015-2789-5","volume":"76","author":"K Kudo","year":"2015","unstructured":"Kudo K, Hotta K, Ichihara E et al (2015) Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. Cancer Chemother Pharmacol 76:251\u2013256","journal-title":"Cancer Chemother Pharmacol"},{"key":"2696_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00280-015-2910-9","volume":"77","author":"K Kudo","year":"2016","unstructured":"Kudo K, Hotta K, Bessho A et al (2016) Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 77:1005\u20131009","journal-title":"Cancer Chemother Pharmacol"},{"key":"2696_CR6","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00280-016-3146-z","volume":"78","author":"N Oda","year":"2016","unstructured":"Oda N, Hotta K, Yoshioka H et al (2016) Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 78:941\u2013947","journal-title":"Cancer Chemother Pharmacol"},{"key":"2696_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.bbrc.2017.10.175","volume":"495","author":"T Tamura","year":"2018","unstructured":"Tamura T, Kato Y, Ohashi K et al (2018) Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. Biochem Biophys Res Commun 495:360\u2013367","journal-title":"Biochem Biophys Res Commun"},{"key":"2696_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113\u2013125","journal-title":"N Engl J Med"},{"issue":"1","key":"2696_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D et al (2020) Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382(1):41\u201350","journal-title":"N Engl J Med"},{"key":"2696_CR10","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1200\/JCO.2009.24.7577","volume":"28","author":"Y Segawa","year":"2010","unstructured":"Segawa Y, Kiura K, Takigawa N et al (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28:3299\u20133306","journal-title":"J Clin Oncol"},{"key":"2696_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","volume":"34","author":"S Senan","year":"2016","unstructured":"Senan S, Brade A, Wang LH et al (2016) PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953\u2013962","journal-title":"J Clin Oncol"},{"key":"2696_CR12","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1200\/JCO.2009.24.5050","volume":"28","author":"N Yamamoto","year":"2010","unstructured":"Yamamoto N, Nakagawa K, Nishimura Y et al (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739\u20133745","journal-title":"J Clin Oncol"},{"key":"2696_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/JTO.0b013e31816e2ea3","volume":"3","author":"S Kuyama","year":"2008","unstructured":"Kuyama S, Hotta K, Tabata M et al (2008) Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 3:477\u2013482","journal-title":"J Thorac Oncol"},{"key":"2696_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.6025","volume":"29","author":"K Hotta","year":"2011","unstructured":"Hotta K, Takigawa N, Matsuo K et al (2011) Cure- or care-oriented regimen for stage III non-small-cell lung cancer? J Clin Oncol 29:e320","journal-title":"J Clin Oncol"},{"key":"2696_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2014.11.001","volume":"87","author":"N Nogami","year":"2015","unstructured":"Nogami N, Takigawa N, Hotta K et al (2015) A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501. Lung Cancer 87:141\u2013147","journal-title":"Lung Cancer"},{"key":"2696_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100191","volume":"6","author":"K Hotta","year":"2021","unstructured":"Hotta K, Saeki S, Yamaguchi M et al (2021) Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902\/OLCSG0905 phase II study. ESMO Open 6:100191","journal-title":"ESMO Open"},{"issue":"Suppl","key":"2696_CR17","doi-asserted-by":"publisher","first-page":"7045","DOI":"10.1200\/jco.2012.30.15_suppl.7045","volume":"30","author":"A Hisamoto","year":"2012","unstructured":"Hisamoto A, Sasaki J, Takigawa N et al (2012) A phase II trial of induction gefitinib monotherapy followed by cisplatin-docetaxel and concurrent thoracic irradiation in patients with EGFR-mutant locally advanced non-small-cell lung cancer (LA-NSCLC): LOGIK0902\/OLCSG0905 intergroup trial. J Clin Oncol 30(Suppl):7045","journal-title":"J Clin Oncol"},{"key":"2696_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cllc.2015.08.004","volume":"17","author":"K Hotta","year":"2016","unstructured":"Hotta K, Sasaki J, Saeki S et al (2016) Gefitinib combined with standard chemoradiotherapy in EGFR-mutant locally advanced non-small-cell lung cancer: the LOGIK0902\/OLCSG0905 intergroup study protocol. Clin Lung Cancer 17:75\u201379","journal-title":"Clin Lung Cancer"},{"key":"2696_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1200\/JCO.2006.08.2826","volume":"25","author":"VW Rusch","year":"2007","unstructured":"Rusch VW, Giroux DJ, Kraut MJ et al (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25:313\u2013318","journal-title":"J Clin Oncol"},{"key":"2696_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/annonc\/mdv063","volume":"26","author":"S Sugawara","year":"2015","unstructured":"Sugawara S, Oizumi S, Minato K et al (2015) Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005\/TCOG0902. Ann Oncol 26:888\u2013894","journal-title":"Ann Oncol"},{"key":"2696_CR21","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1097\/JTO.0000000000000675","volume":"10","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Hida T, Oya Y et al (2015) EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma. J Thorac Oncol 10:1720\u20131725","journal-title":"J Thorac Oncol"},{"key":"2696_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijrobp.2014.08.344","volume":"91","author":"S Yagishita","year":"2015","unstructured":"Yagishita S, Horinouchi H, Katsui Taniyama T et al (2015) Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 91:140\u2013148","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2696_CR23","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1016\/j.cllc.2019.02.021","volume":"20","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Kageyama SI, Niho S et al (2019) Impact of EGFR mutation and ALK 5ranslocation on recurrence pattern after definitive chemoradiotherapy for inoperable stage III non-squamous non-small-cell lung cancer. Clin Lung Cancer 20:e256\u2013e264","journal-title":"Clin Lung Cancer"},{"key":"2696_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/COC.0b013e31826e04f9","volume":"37","author":"H Akamatsu","year":"2014","unstructured":"Akamatsu H, Kaira K, Murakami H et al (2014) The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who received concurrent chemoradiotherapy. Am J Clin Oncol 37:144\u2013147","journal-title":"Am J Clin Oncol"},{"key":"2696_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2402614","volume":"391","author":"S Lu","year":"2024","unstructured":"Lu S, Kato T, Dong X et al (2024) Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 391:585\u2013597","journal-title":"N Engl J Med"},{"key":"2696_CR26","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/j.lpm.2013.06.012","volume":"42","author":"C Chargari","year":"2013","unstructured":"Chargari C, Riet F, Mazevet M et al (2013) Complications of thoracic radiation therapy. Presse Med 42:e342-351","journal-title":"Presse Med"},{"key":"2696_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","volume":"47","author":"DW Denning","year":"2016","unstructured":"Denning DW, Cadranel J, Beigelman-Aubry C et al (2016) Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 47:45\u201368","journal-title":"Eur Respir J"},{"key":"2696_CR28","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/S1470-2045(08)70255-9","volume":"9","author":"S Vento","year":"2008","unstructured":"Vento S, Cainelli F, Temesgen Z (2008) Lung infections after cancer chemotherapy. Lancet Oncol 9:982\u2013992","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02696-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02696-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T07:49:47Z","timestamp":1740037787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02696-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2696"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02696-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Katsuyuki Hotta has personal fees from AZ, Chugai, Lilly, MSD, BMS, Ono, Boehringer-Ingelheim, NipponKayaku, Amgen, Taiho, Merck, and grants from MSD, AZ, Chugai, Lilly, BMS, Abbvie, Ono. Daijiro Harada has personal fees from Takeda Pharmaceutical Company Limited., Eli Lilly and Company, CHUGAI PHARMACEUTICAL CO., LTD., AstraZeneca K.K., TAIHO PHARMACEUTICAL CO., LTD., ONO PHARMACEUTICAL CO., LTD., Bristol-Myers Squibb Company, TOWA PHRMACEUTICAL CO., LTD., Nippon Boehringer Ingelheim Co., Ltd., and grants from MSD K.K., AstraZeneca K.K., Pfizer Japan Inc., ONO PHARMACEUTICAL CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., Eli Lilly and Company, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited. Akihiro Bessho has personal fees from AstraZeneca, Chugai Pharmaceutical, Bristol-Myers Squibb, MSD, ONO Pharmaceutical, Eli Lilly, Daiichi Sankyo, Taiho Pharmaceutical, Boehringer Ingelheim, and grants from AstraZeneca, Chugai Pharmaceutical, MSD, Samsung Bioepis. Kentaro Tanaka has personal fees from AstraZeneca, Chugai, Johnson and Johnson, Nippon Boehringer Ingelheim. Koji Inoue has personal fees from AZ, Ono, Takeda, MSD, Daiichi Sankyo, Boehringer Ingelheim, Amgen, Lilly, Taiho. Kenichi Gemba has personal fees from Boehringer Ingelheim, BMS, AZ, MSD, Merck, Insmed, Lilly, Taiho, Chugai, NipponKayaku, Takeda. Toshio Kubo has personal fee from AstraZeneca. Eiki Ichihara has personal fees from AstraZeneca K.K., Novartis, Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Pfizer, Bristol-Myers Squibb Co. Ltd., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Boehringer Ingelheim, and receipt of equipment, materials or drugs from Janssen Pharmaceutical K.K., Astellas pharma, and grant from Janssen Pharmaceutical K.K. Hiromi Watanabe has personal fees from AZ, Chugai, Lilly. Kuniaki Katsui has personal fee from Accuray. Kenji Sugio has personal fees from AstraZeneca, Chugai, MSD, Eli Lilly Japan and grants from Chugai, MSD, Eli Lilly Japan, Daiichi Sankyo. Katsuyuki Kiura has personal fees from TAIHO Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., DAIICHI SANKYO COMPANY, LIMITED, Eli Lilly Japan K.K., Bristol-Myers Squibb K.K., Pfizer Japan Inc., Merck Biopharma Co., Ltd., Takeda Pharmaceutical Company Limited, Nippon Kayaku Co., Ltd., NIPRO PHARMA CORPORATION, CHUGAI PHARMACEUTICAL CO., LTD., AstraZeneca K.K., Novartis Pharma K.K., ONO PHARMACEUTICAL CO., LTD. and grants from TAIHO Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., ONO PHARMACEUTICAL CO., LTD., CHUGAI PHARMACEUTICAL CO., LTD., Nippon Kayaku Co., Ltd., TEIJIN PHARMA LIMITED., Shionogi Pharma Co., Ltd., Novartis Pharma K.K., Takeda Pharmaceutical Company Limited, KYORIN Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K.K., Pfizer Japan Inc. The other authors do not have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}